{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-000076","form_type":"8-K","ticker":"SNOA","cik":"0001367083","company_name":"Sonoma Pharmaceuticals, Inc.","filed_at":"2025-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.441378+00:00","generated_at":"2026-05-28T13:52:08.940435+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Sonoma Pharma grants 7,500 options to directors and 10,000 RSUs to each top executive","bullets":["Non-employee directors each received 7,500 options at $2.68, vesting over three years.","CEO Amy Trombly granted 10,000 RSUs; vesting at 6, 18, and 24 months.","CFO Jerry Dvonch and COO Bruce Thornton each granted 10,000 RSUs with same vesting schedule.","All awards vest upon change of control as part of annual equity grant program."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-000076","json":"https://secwatch.observer/filing/0001683168-25-000076.json","markdown":"https://secwatch.observer/filing/0001683168-25-000076.md","text":"https://secwatch.observer/filing/0001683168-25-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367083/000168316825000076/0001683168-25-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367083/000168316825000076/sonoma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T13:52:08.940435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}